To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts
of participants with relapsed or refractory monocytic AML and CMML in order to estimate the
maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended
Phase 2 dose (RP2D) and dose schedule as monotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Immune-Onc Therapeutics Inc
Collaborator:
California Institute for Regenerative Medicine (CIRM)